Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial

[1]  H. Kim,et al.  Evaluating the impact of the nationwide public–private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis , 2021, PLoS medicine.

[2]  John L. Johnson,et al.  Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. , 2021, The New England journal of medicine.

[3]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[4]  W. Hoefsloot,et al.  High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre , 2019, PloS one.

[5]  Robin J. Svensson,et al.  Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations , 2018, The Journal of infectious diseases.

[6]  Robin J. Svensson,et al.  The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Diacon,et al.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial , 2017, The Lancet. Infectious diseases.

[8]  S. Birch,et al.  Does treatment collection and observation each day keep the patient away? An analysis of the determinants of adherence among patients with Tuberculosis in South Africa. , 2016, Health policy and planning.

[9]  D. Mitchison,et al.  High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo , 2015, Front. Microbiol..

[10]  A. Diacon,et al.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. , 2015, American journal of respiratory and critical care medicine.

[11]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[12]  B. D. de Jong,et al.  A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.

[13]  P. Butcher,et al.  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.

[14]  W. Mackenzie,et al.  Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  A. Diacon,et al.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  K. Steingart,et al.  Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  G. Drusano,et al.  Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.

[18]  E. Kantharaj,et al.  Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[19]  D. Mitchison,et al.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  Jae Ho Lee,et al.  Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. , 2019, The Lancet. Infectious diseases.

[21]  J. Yim,et al.  Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..